Alexion is a global biopharmaceutical company focused on developing and delivering life-changing therapies for patients with devastating and rare diseases.
Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.
Alexion was established in the U.S. in 1992 and became a public company in 1996 (NASDAQ: ALXN). We were added to the NASDAQ-100 Index in 2011 and to the Standard & Poor's 500 Index in 2012. Alexion’s global headquarters are currently in New Haven, Conn. In September 2017, the Company announced that it would relocate its headquarters to Boston, Mass., by mid-2018 and that New Haven would serve as the Company’s Center of Excellence for its world-class complement research and process development teams. Alexion's employees around the world serve patients in approximately 50 countries.
OUR BREAKTHROUGH PRODUCTS
Alexion developed Soliris® (eculizumab), the world's first approved terminal complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening, ultra-rare disorders caused by uncontrolled complement activation. Soliris is also approved in the European Union for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Marketing applications for Soliris for the treatment of this ultra-rare subset of MG patients have been accepted for review in the U.S. and Japan.
Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders—Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D).
Alexion’s ambition is to be the global leader in rare diseases by leveraging our 20+ years of expertise in complement biology and our capabilities in hematology, nephrology, neurology and metabolic disorders to bring additional life-changing therapies to patients.